Cytodyn Inc (CYDY)

[CTMedic]

Irishvox,

There is the ability to label leronlimab, but I am quite convinced that this is not the case in CD10 or CD12. The results of the trials are what counts. Labeling would be very appropriate if trying to determine MOA, duration of receptor occupancy, etc.

In the case of the trials, the clinical results are the metrics by which leronlimab will be judged.

I listened to the Tedx Traverse city talk, but not recently.

I believe Dr. Patterson stated that, either in the Ted talk and/or one of the Youtube interviews, that they were seeing "interesting results" after Leronlimab administration.

I took this to mean that they were seeing marked immune restoration (CD4 and CD8 levels and ratio), which was indicative of which patients received Leronlimab.